March 2021 PMID 33663731

Outcomes 2 Years After Transcatheter Aortic Valve Replacement in Patients at Low Surgical Risk.

Martin B Leon, Michael J Mack, Rebecca T Hahn, Vinod H Thourani, Raj Makkar, Susheel K Kodali, Maria C Alu, Mahesh V Madhavan, Katherine H Chau, Mark Russo, Samir R Kapadia, S Chris Malaisrie, David J Cohen, Philipp Blanke, Jonathon A Leipsic

Download social card

Mentions

125

Peak: 99 in Mar 2021

across 4 sources since Mar 2021

Extended reach

684,043

potential audience

Total likes

118

Video views

948

Mentions per month

Mar 2021 – Mar 2024

Where it's discussed

X / Twitter106 posts
News14 articles
YouTube3 videos
Facebook2 posts

AI synopsis

What people are saying

Many posts summarize the findings, such as noting that the primary endpoint for the TAVR procedure is significantly lower than surgery, with some highlighting the increased valve thrombosis rate as a relevant concern. The choice of words, like 'significantly lower' and 'initial differences diminished,' conveys a formal yet urgent tone, illustrating the complexity of the findings and stimulating further discussion among healthcare professionals.

AgreementModerate agreement

The majority of discussions reflect a supportive stance toward the study, although a few raise concerns about specific outcomes.

InterestHigh interest

There is a notable level of curiosity about the findings, indicating that followers are keen to engage with the new information.

EngagementModerate engagement

While many posts reiterate key findings, only a few dive into deeper analysis or implications, suggesting moderate engagement.

ImpactModerate impact

The perceived influence of the study is present but mixed, with some users pointing out limitations that may temper its overall impact.

Abstract in brief

The PARTNER 3 trial showed that transcatheter aortic valve replacement (TAVR) is more effective than surgery for low-risk patients with severe aortic stenosis, particularly in reducing the rates of death, stroke, or rehospitalization at 1 and 2 years.
At the 2-year mark, the primary endpoint (death, stroke, rehospitalization) remained significantly lower for TAVR compared to surgery (11.5% vs 17.4%), although the statistical significance for death and stroke alone was less clear.
Despite an increase in valve thrombosis events post-TAVR, overall health outcomes and echocardiographic findings for both procedures were similar at 2 years, indicating TAVR remains a strong alternative to surgery for this patient group.

Read the full abstract

All mentions

Aortic Valve Replacement: Insights from the AVATAR Trial Results

This video critically discusses the effectiveness of early surgical aortic valve replacement versus conservative treatment in asymptomatic severe aortic stenosis. We explore recent evidence on SHD interventions and…

TGH Advanced Perioperative Imaging Lab · Dec 25, 2022 800 views

TAVI, SAVR, PCI and low risk patients

NB Heart Centre CV Rounds · May 7, 2021 123 views

Sudden Cardiac Death in Sports and Coffee's Health Effects

This week, we discuss exercise-related sudden cardiac death and new findings in TAVI data. The podcast also explores the health effects of coffee on cardiac activity and physical performance. Join John Mandrola, MD, for…

Medscape · Mar 27, 2024 18 views

Mar 19, 2021 This Week in Cardiology Podcast

Medscape · Mar 27, 2024 8 views

El Barto

@goez_gaviria · X

RT @fcardioinfantil: En nuestro #BlogDeFellows de hoy, hablaremos sobre "Resultados 2 años después del reemplazo valvular aórtico percutáne…

Jan 25, 2024 · 1 share · 69 followers View post →

Fundación Cardioinfantil - LaCardio

@fcardioinfantil · X

En nuestro #BlogDeFellows de hoy, hablaremos sobre "Resultados 2 años después del reemplazo valvular aórtico percutáneo en pacientes con bajo riesgo quirúrgico.". Encuéntralo completo aquí: https://t.co/Ro9WsyjP0r #Educación #Ciencia #Cardiología #Lectura

Jan 25, 2024 · 1 like · 1 share · 19,628 followers View post →

محمد سعد العدوي

@mhmdsd30801085 · X

RT @AhmedSaadEladwy: Outcomes 2 Years After Transcatheter Aortic Valve Replacement in Patients at Low Surgical Risk https://t.co/1iybOVXwPA

Jul 30, 2023 · 1 share · 347 followers View post →

Ahmed Saad Eladawy

@AhmedSaadEladwy · X

Outcomes 2 Years After Transcatheter Aortic Valve Replacement in Patients at Low Surgical Risk https://t.co/1iybOVXwPA

Sep 21, 2021 · 2 likes · 1 share · 180 followers View post →

Trip Database

@tripdatabase · X

New2Trip: Outcomes 2 Years After Transcatheter Aortic Valve Replacement in Patients at Low Surgical Risk https://t.co/6DPVi3KufH

Apr 9, 2021 · 4,415 followers View post →

Ashish Tiwari, M.D. D.M. (Cardiology)

@DrAshishCardio · X

RT @hahn_rt: Just Published: PARTNER 3, 2Yr https://t.co/FZKs3uVxtH Primary endpoint remained significantly lower w/ TAVR vs SAVR, but init…

Apr 6, 2021 · 72 shares · 852 followers View post →

Trip Database

@tripdatabase · X

New2Trip: Outcomes 2 Years After Transcatheter Aortic Valve Replacement in Patients at Low Surgical Risk https://t.co/6DPVi3KufH

Apr 4, 2021 · 4,415 followers View post →

Trip Database

@tripdatabase · X

New2Trip: Outcomes 2 Years After Transcatheter Aortic Valve Replacement in Patients at Low Surgical Risk https://t.co/6DPVi4257f

Mar 23, 2021 · 4,415 followers View post →

karthikeyan gopal

@gkarkey · X

RT @PPibarot: PARTNER 3 - 2 Years data just published in JACC. The primary endpoint remained significantly lower with TAVR versus SAVR but…

Mar 22, 2021 · 53 shares · 115 followers View post →

Univ.-Prof. Dr. Ralph Stephan von Bardeleben

@vonBardelebenRS · X

RT @hahn_rt: Just Published: PARTNER 3, 2Yr https://t.co/FZKs3uVxtH Primary endpoint remained significantly lower w/ TAVR vs SAVR, but init…

Mar 20, 2021 · 72 shares · 3,069 followers View post →

Linda

@wordfinga · X

RT @AshishPershad: Outcomes 2 Years After Transcatheter Aortic Valve Replacement in Patients at Low Surgical Risk: https://t.co/AySOX3NrDj.…

Mar 12, 2021 · 5 shares · 4,596 followers View post →

AG5-Kardiovaskulärer Ultraschall

@Echo_DGK_GER · X

RT @hahn_rt: Just Published: PARTNER 3, 2Yr https://t.co/FZKs3uVxtH Primary endpoint remained significantly lower w/ TAVR vs SAVR, but init…

Mar 10, 2021 · 72 shares · 1,665 followers View post →

rafaelportalupp

@rafaelportalup2 · X

RT @PPibarot: PARTNER 3 - 2 Years data just published in JACC. The primary endpoint remained significantly lower with TAVR versus SAVR but…

Mar 9, 2021 · 53 shares · 457 followers View post →

RUI M S ALMEIDA

@RMSSAA · X

RT @AshishPershad: Outcomes 2 Years After Transcatheter Aortic Valve Replacement in Patients at Low Surgical Risk: https://t.co/AySOX3NrDj.…

Mar 8, 2021 · 5 shares · 752 followers View post →

Philippe Pibarot

@PPibarot · X

RT @AshishPershad: Outcomes 2 Years After Transcatheter Aortic Valve Replacement in Patients at Low Surgical Risk: https://t.co/AySOX3NrDj.…

Mar 7, 2021 · 5 shares · 6,840 followers View post →

Chris Kairis

@chriskairis1 · X

Outcomes 2 Years After Transcatheter Aortic Valve Replacement in Patients at Low Surgical Risk: initial differences in death and stroke favoring TAVR were diminished and patients who underwent TAVR had increased valve thrombosis compared with surgery. https://t.co/WsM6PbYjwh

Mar 7, 2021 · 421 followers View post →

Ivandito Kuntjoro MD, FACC, FESC, FAMS, FAPSIC

@Ditongaje · X

RT @PPibarot: PARTNER 3 - 2 Years data just published in JACC. The primary endpoint remained significantly lower with TAVR versus SAVR but…

Mar 7, 2021 · 53 shares · 747 followers View post →

Mark Schuuring

@mjschuuring · X

RT @PPibarot: PARTNER 3 - 2 Years data just published in JACC. The primary endpoint remained significantly lower with TAVR versus SAVR but…

Mar 7, 2021 · 53 shares · 1,566 followers View post →

Alessia Gimelli

@alessia_gimelli · X

RT @PPibarot: PARTNER 3 - 2 Years data just published in JACC. The primary endpoint remained significantly lower with TAVR versus SAVR but…

Mar 7, 2021 · 53 shares · 3,589 followers View post →

Linda

@wordfinga · X

RT @CardioIAN: @CardioIAN #CardioTwitter #CardioTwitter @mmamas1973 @Hragy @AlainBouchardmd @MihaiTrofenciuc @pabeda1 @Pooh_Velagapudi @mir…

Mar 6, 2021 · 2 shares · 4,596 followers View post →

Linda

@wordfinga · X

https://t.co/0X6XYgDiT4

Mar 6, 2021 · 4,596 followers View post →

Sophia Roberts Pyeatte, MD

@SophiaRPyeatte · X

RT @TFaggionVinholo: Outcomes 2 Years After Transcatheter Aortic Valve Replacement in Patients at Low Surgical Risk | Journal of the Americ…

Mar 6, 2021 · 1 share · 1,806 followers View post →

Thor Edvardsen

@ThorEdvardsen · X

RT @PPibarot: PARTNER 3 - 2 Years data just published in JACC. The primary endpoint remained significantly lower with TAVR versus SAVR but…

Mar 6, 2021 · 53 shares · 4,583 followers View post →

Urooj Fatima MD FACC FSCAI

@uroojmd1 · X

RT @AshishPershad: Outcomes 2 Years After Transcatheter Aortic Valve Replacement in Patients at Low Surgical Risk: https://t.co/AySOX3NrDj.…

Mar 6, 2021 · 5 shares · 921 followers View post →

Ashish Pershad

@AshishPershad · X

Mar 6, 2021 · 15 likes · 5 shares · 1,638 followers View post →

Thais Faggion Vinholo

@TFaggionVinholo · X

Outcomes 2 Years After Transcatheter Aortic Valve Replacement in Patients at Low Surgical Risk | Journal of the American College of Cardiology https://t.co/LHUkMFRisR

Mar 6, 2021 · 11 likes · 1 share · 2,285 followers View post →

Jackie K. Olive, MD

@JackieKOlive · X

Outcomes 2 Years After Transcatheter Aortic Valve Replacement in Patients at Low Surgical Risk: https://t.co/gcSUwDe7xv @JACCJournals #TSSMN

Mar 6, 2021 · 7 likes · 3,479 followers View post →

Radial AF

@jwhansen1983 · X

RT @hahn_rt: Just Published: PARTNER 3, 2Yr https://t.co/FZKs3uVxtH Primary endpoint remained significantly lower w/ TAVR vs SAVR, but init…

Mar 6, 2021 · 72 shares · 620 followers View post →

Rahul Sharma, MD

@Rahul2282Sharma · X

RT @hahn_rt: Just Published: PARTNER 3, 2Yr https://t.co/FZKs3uVxtH Primary endpoint remained significantly lower w/ TAVR vs SAVR, but init…

Mar 6, 2021 · 72 shares · 3,451 followers View post →

AKiyoshi, MD, PhD

@akiyoshiMD · X

Outcomes 2 Years After Transcatheter Aortic Valve Replacement in Patients at Low Surgical Risk: https://t.co/1KATgWZnIf TAVR vs. surgery primary endpoint 11.5% vs. 17.4% valve thrombosis 2.6% vs. 0.7% https://t.co/j9wbD8VQsU

Mar 5, 2021 · 920 followers View post →

Osama Bisht

@Obisht · X

RT @JACCJournals: What are the 2-year outcomes after #TAVR for low surgical risk patients? Results of the PARTNER 3 study are published i…

Mar 5, 2021 · 13 shares · 6,404 followers View post →

TAVR Bot

@TAVRBot · X

RT @JACCJournals: What are the 2-year outcomes after #TAVR for low surgical risk patients? Results of the PARTNER 3 study are published i…

Mar 5, 2021 · 13 shares · 2,905 followers View post →

Ivana Garza

@garzaivanav · X

RT @JACCJournals: What are the 2-year outcomes after #TAVR for low surgical risk patients? Results of the PARTNER 3 study are published i…

Mar 5, 2021 · 13 shares · 108 followers View post →

W. David Merryman

@merrymanlab · X

RT @JACCJournals: What are the 2-year outcomes after #TAVR for low surgical risk patients? Results of the PARTNER 3 study are published i…

Mar 5, 2021 · 13 shares · 1,655 followers View post →

JACC Journals

@JACCJournals · X

Mar 5, 2021 · 46 likes · 13 shares · 114,451 followers View post →

Yuta Kobayashi

@yt_reggae · X

RT @yt_reggae: では最近でたPARTNER3の2年後データ。こちらも同様にcatch upの傾向があるんですよね、残念ながら。とはいえ、Editorial commentにもあるように、TAVI1-2年後のdeathは非心臓死が4/7と多いですし、今後10年後まで…

Mar 3, 2021 · 1 share · 1,377 followers View post →

Yuta Kobayashi

@yt_reggae · X

では最近でたPARTNER3の2年後データ。こちらも同様にcatch upの傾向があるんですよね、残念ながら。とはいえ、Editorial commentにもあるように、TAVI1-2年後のdeathは非心臓死が4/7と多いですし、今後10年後までフォローとなるのでデータをまちたいところです。 https://t.co/QJZZwvpmFH

Mar 3, 2021 · 3 likes · 1 share · 1,377 followers View post →

Joe Doyle

@Rocket2010 · X

RT @hahn_rt: Just Published: PARTNER 3, 2Yr https://t.co/FZKs3uVxtH Primary endpoint remained significantly lower w/ TAVR vs SAVR, but init…

Mar 3, 2021 · 72 shares · 323 followers View post →

Philippe Genereux

@PhilGenereuxMD · X

RT @hahn_rt: Just Published: PARTNER 3, 2Yr https://t.co/FZKs3uVxtH Primary endpoint remained significantly lower w/ TAVR vs SAVR, but init…

Mar 3, 2021 · 72 shares · 4,351 followers View post →

Dr Gomez Doblas

@DrDoblas · X

Outcomes 2 Years After Transcatheter Aortic Valve Replacement in Patients at Low Surgical Risk: https://t.co/ua4d1ADTMT

Mar 3, 2021 · 1 like · 2,991 followers View post →

Timm Matthiesen

@MatthiesenTimm · X

RT @hahn_rt: Just Published: PARTNER 3, 2Yr https://t.co/FZKs3uVxtH Primary endpoint remained significantly lower w/ TAVR vs SAVR, but init…

Mar 3, 2021 · 72 shares · 920 followers View post →

Linda

@wordfinga · X

RT @hahn_rt: Just Published: PARTNER 3, 2Yr https://t.co/FZKs3uVxtH Primary endpoint remained significantly lower w/ TAVR vs SAVR, but init…

Mar 3, 2021 · 72 shares · 4,596 followers View post →

Poonam Velagapudi

@Pooh_Velagapudi · X

RT @hahn_rt: Just Published: PARTNER 3, 2Yr https://t.co/FZKs3uVxtH Primary endpoint remained significantly lower w/ TAVR vs SAVR, but init…

Mar 3, 2021 · 72 shares · 11,715 followers View post →

Oury Cécile

@CecileOury · X

RT @PPibarot: PARTNER 3 - 2 Years data just published in JACC. The primary endpoint remained significantly lower with TAVR versus SAVR but…

Mar 3, 2021 · 53 shares · 177 followers View post →

Debbie Mac Pherson

@MVPASMR · X

RT @PPibarot: PARTNER 3 - 2 Years data just published in JACC. The primary endpoint remained significantly lower with TAVR versus SAVR but…

Mar 2, 2021 · 53 shares · 37 followers View post →

Hugo Zanella

@hzanellamd · X

RT @hahn_rt: Just Published: PARTNER 3, 2Yr https://t.co/FZKs3uVxtH Primary endpoint remained significantly lower w/ TAVR vs SAVR, but init…

Mar 2, 2021 · 72 shares · 1,018 followers View post →

Khalid Minhas, MD FACC

@minhaskh · X

RT @HeartOTXHeartMD: At 2yrs, the primary endpoint remained significantly lower w #TAVI versus surgery, but initial differences in death an…

Mar 2, 2021 · 1 share · 11,350 followers View post →

Luciano de Figueiredo Aguiar Filho

@luc_aguiarf · X

RT @PPibarot: PARTNER 3 - 2 Years data just published in JACC. The primary endpoint remained significantly lower with TAVR versus SAVR but…

Mar 2, 2021 · 53 shares · 89 followers View post →

KMoMD

@KMoMD1 · X

RT @PPibarot: PARTNER 3 - 2 Years data just published in JACC. The primary endpoint remained significantly lower with TAVR versus SAVR but…

Mar 2, 2021 · 53 shares · 3 followers View post →

Blazej Michalski

@bwmichalski · X

RT @PPibarot: PARTNER 3 - 2 Years data just published in JACC. The primary endpoint remained significantly lower with TAVR versus SAVR but…

Mar 2, 2021 · 53 shares · 491 followers View post →

Ramon Sanchez

@Sanchez1153 · X

RT @hahn_rt: Just Published: PARTNER 3, 2Yr https://t.co/FZKs3uVxtH Primary endpoint remained significantly lower w/ TAVR vs SAVR, but init…

Mar 2, 2021 · 72 shares · 52 followers View post →

Abdulla A. Damluji, MD, PhD

@DrDamluji · X

Outcomes 2 Years After Transcatheter Aortic Valve Replacement in Patients at Low Surgical Risk: Longer term real-world outcomes will likely come out soon Re: @djc795 https://t.co/9FkrhC1eyY https://t.co/3yQ7DjXNE1

Mar 2, 2021 · 3 likes · 15,804 followers View post →

Simona Sperlongano

@S_Sperlongano · X

RT @PPibarot: PARTNER 3 - 2 Years data just published in JACC. The primary endpoint remained significantly lower with TAVR versus SAVR but…

Mar 2, 2021 · 53 shares · 110 followers View post →

Nicolas Areco

@NicolasAreco3 · X

RT @hahn_rt: Just Published: PARTNER 3, 2Yr https://t.co/FZKs3uVxtH Primary endpoint remained significantly lower w/ TAVR vs SAVR, but init…

Mar 2, 2021 · 72 shares · 150 followers View post →

Aly Ghoneim MD, Ph.D, FRCSC

@drAly_G · X

RT @hahn_rt: Just Published: PARTNER 3, 2Yr https://t.co/FZKs3uVxtH Primary endpoint remained significantly lower w/ TAVR vs SAVR, but init…

Mar 2, 2021 · 72 shares · 828 followers View post →

Mihai Trofenciuc

@MihaiTrofenciuc · X

RT @CardioIAN: @CardioIAN #CardioTwitter #CardioTwitter @mmamas1973 @Hragy @AlainBouchardmd @MihaiTrofenciuc @pabeda1 @Pooh_Velagapudi @mir…

Mar 2, 2021 · 2 shares · 3,875 followers View post →

Ash Paul

@pash22 · X

RT @hahn_rt: Just Published: PARTNER 3, 2Yr https://t.co/FZKs3uVxtH Primary endpoint remained significantly lower w/ TAVR vs SAVR, but init…

Mar 2, 2021 · 72 shares · 32,248 followers View post →

IANCARDIOLOGY

@CardioIAN · X

@CardioIAN #CardioTwitter #CardioTwitter @mmamas1973 @Hragy @AlainBouchardmd @MihaiTrofenciuc @pabeda1 @Pooh_Velagapudi @mirvatalasnag https://t.co/f4URc2zwyf

Mar 2, 2021 · 4 likes · 2 shares · 8,260 followers View post →

happy anesth

@kmyk08315265 · X

RT @hahn_rt: Just Published: PARTNER 3, 2Yr https://t.co/FZKs3uVxtH Primary endpoint remained significantly lower w/ TAVR vs SAVR, but init…

Mar 2, 2021 · 72 shares · 545 followers View post →

Solmaz Assa

@drsoli4030 · X

RT @hahn_rt: Just Published: PARTNER 3, 2Yr https://t.co/FZKs3uVxtH Primary endpoint remained significantly lower w/ TAVR vs SAVR, but init…

Mar 2, 2021 · 72 shares · 168 followers View post →

Yuji Matsuda MD., PhD.

@mtyjcardiology · X

RT @hahn_rt: Just Published: PARTNER 3, 2Yr https://t.co/FZKs3uVxtH Primary endpoint remained significantly lower w/ TAVR vs SAVR, but init…

Mar 2, 2021 · 72 shares · 33 followers View post →

Jim Nolan

@nolanjimradial · X

https://t.co/sQDB6QPxKD

Mar 2, 2021 · 5 likes · 5,980 followers View post →

Lucas Cardoso

@CardosoLucasMD · X

RT @PPibarot: PARTNER 3 - 2 Years data just published in JACC. The primary endpoint remained significantly lower with TAVR versus SAVR but…

Mar 2, 2021 · 53 shares · 80 followers View post →

Doralisa Morrone

@DoryMD · X

RT @PPibarot: PARTNER 3 - 2 Years data just published in JACC. The primary endpoint remained significantly lower with TAVR versus SAVR but…

Mar 2, 2021 · 53 shares · 274 followers View post →

Jeison Torrens Soto

@torrens_soto · X

RT @hahn_rt: Just Published: PARTNER 3, 2Yr https://t.co/FZKs3uVxtH Primary endpoint remained significantly lower w/ TAVR vs SAVR, but init…

Mar 2, 2021 · 72 shares · 202 followers View post →

UnimpressiveOverall

@UnimpressiveO · X

RT @hahn_rt: Just Published: PARTNER 3, 2Yr https://t.co/FZKs3uVxtH Primary endpoint remained significantly lower w/ TAVR vs SAVR, but init…

Mar 2, 2021 · 72 shares · 434 followers View post →

JACC Journals

@JACCJournals · X

RT @hahn_rt: Just Published: PARTNER 3, 2Yr https://t.co/FZKs3uVxtH Primary endpoint remained significantly lower w/ TAVR vs SAVR, but init…

Mar 2, 2021 · 72 shares · 114,451 followers View post →

John P Erwin III MD MBA MACC (#BigPoppy )

@HeartOTXHeartMD · X

Mar 2, 2021 · 4 likes · 1 share · 39,659 followers View post →

Alessandro Sticchi

@Sticchi_Alex · X

RT @hahn_rt: Just Published: PARTNER 3, 2Yr https://t.co/FZKs3uVxtH Primary endpoint remained significantly lower w/ TAVR vs SAVR, but init…

Mar 2, 2021 · 72 shares · 3,888 followers View post →

INC Cath Lab

@INC_CathLab · X

RT @PPibarot: PARTNER 3 - 2 Years data just published in JACC. The primary endpoint remained significantly lower with TAVR versus SAVR but…

Mar 2, 2021 · 53 shares · 4,038 followers View post →

Mamas A. Mamas

@mmamas1973 · X

RT @hahn_rt: Just Published: PARTNER 3, 2Yr https://t.co/FZKs3uVxtH Primary endpoint remained significantly lower w/ TAVR vs SAVR, but init…

Mar 2, 2021 · 72 shares · 79,777 followers View post →

د . احمد سمان

@Ahmed43101178 · X

RT @hahn_rt: Just Published: PARTNER 3, 2Yr https://t.co/FZKs3uVxtH Primary endpoint remained significantly lower w/ TAVR vs SAVR, but init…

Mar 2, 2021 · 72 shares · 6,356 followers View post →

Ignacio J. Amat

@ignamatsant · X

RT @PPibarot: PARTNER 3 - 2 Years data just published in JACC. The primary endpoint remained significantly lower with TAVR versus SAVR but…

Mar 2, 2021 · 53 shares · 4,745 followers View post →

Hector Ortiz Mendoza

@Hector_E_Ortiz · X

RT @PPibarot: PARTNER 3 - 2 Years data just published in JACC. The primary endpoint remained significantly lower with TAVR versus SAVR but…

Mar 2, 2021 · 53 shares · 384 followers View post →

loops

@echotainment · X

RT @hahn_rt: Just Published: PARTNER 3, 2Yr https://t.co/FZKs3uVxtH Primary endpoint remained significantly lower w/ TAVR vs SAVR, but init…

Mar 2, 2021 · 72 shares · 4,660 followers View post →

American Society of Echocardiography

@ASE360 · X

RT @hahn_rt: Just Published: PARTNER 3, 2Yr https://t.co/FZKs3uVxtH Primary endpoint remained significantly lower w/ TAVR vs SAVR, but init…

Mar 2, 2021 · 72 shares · 33,729 followers View post →

Shazia Afzal, MD, FESC

@DrShazAfzal · X

RT @hahn_rt: Just Published: PARTNER 3, 2Yr https://t.co/FZKs3uVxtH Primary endpoint remained significantly lower w/ TAVR vs SAVR, but init…

Mar 2, 2021 · 72 shares · 314 followers View post →

MuhdNajmiHakim

@najmiannafis · X

RT @hahn_rt: Just Published: PARTNER 3, 2Yr https://t.co/FZKs3uVxtH Primary endpoint remained significantly lower w/ TAVR vs SAVR, but init…

Mar 2, 2021 · 72 shares · 41 followers View post →

Amina

@ARakisheva · X

RT @hahn_rt: Just Published: PARTNER 3, 2Yr https://t.co/FZKs3uVxtH Primary endpoint remained significantly lower w/ TAVR vs SAVR, but init…

Mar 2, 2021 · 72 shares · 592 followers View post →

Toral Patel

@ToralPatelMD · X

RT @hahn_rt: Just Published: PARTNER 3, 2Yr https://t.co/FZKs3uVxtH Primary endpoint remained significantly lower w/ TAVR vs SAVR, but init…

Mar 2, 2021 · 72 shares · 112 followers View post →

Matthew J. Chung

@MatthewChungMD · X

RT @hahn_rt: Just Published: PARTNER 3, 2Yr https://t.co/FZKs3uVxtH Primary endpoint remained significantly lower w/ TAVR vs SAVR, but init…

Mar 2, 2021 · 72 shares · 834 followers View post →

Hoda Hatoum

@DrHodaHatoum · X

RT @hahn_rt: Just Published: PARTNER 3, 2Yr https://t.co/FZKs3uVxtH Primary endpoint remained significantly lower w/ TAVR vs SAVR, but init…

Mar 2, 2021 · 72 shares · 516 followers View post →

Thiruvasagam

@Thiruva90833980 · X

RT @hahn_rt: Just Published: PARTNER 3, 2Yr https://t.co/FZKs3uVxtH Primary endpoint remained significantly lower w/ TAVR vs SAVR, but init…

Mar 2, 2021 · 72 shares · 6 followers View post →

Antonio Augusto Guimarães Lima

@augustolimaa · X

RT @hahn_rt: Just Published: PARTNER 3, 2Yr https://t.co/FZKs3uVxtH Primary endpoint remained significantly lower w/ TAVR vs SAVR, but init…

Mar 2, 2021 · 72 shares · 138 followers View post →

Mauricio Soto V, MD, MSc, FACC

@MauroSotoMD · X

RT @hahn_rt: Just Published: PARTNER 3, 2Yr https://t.co/FZKs3uVxtH Primary endpoint remained significantly lower w/ TAVR vs SAVR, but init…

Mar 2, 2021 · 72 shares · 393 followers View post →

Jayashri Aragam

@AragamJayashri · X

RT @hahn_rt: Just Published: PARTNER 3, 2Yr https://t.co/FZKs3uVxtH Primary endpoint remained significantly lower w/ TAVR vs SAVR, but init…

Mar 2, 2021 · 72 shares · 230 followers View post →

Mathias Orban

@maorban · X

RT @hahn_rt: Just Published: PARTNER 3, 2Yr https://t.co/FZKs3uVxtH Primary endpoint remained significantly lower w/ TAVR vs SAVR, but init…

Mar 2, 2021 · 72 shares · 174 followers View post →

Edu Arroyo

@eduarroyoucar · X

RT @PPibarot: PARTNER 3 - 2 Years data just published in JACC. The primary endpoint remained significantly lower with TAVR versus SAVR but…

Mar 2, 2021 · 53 shares · 416 followers View post →

Max Sayers

@DrMaxSayers · X

RT @hahn_rt: Just Published: PARTNER 3, 2Yr https://t.co/FZKs3uVxtH Primary endpoint remained significantly lower w/ TAVR vs SAVR, but init…

Mar 2, 2021 · 72 shares · 689 followers View post →

Elad Maor

@maor_elad · X

RT @PPibarot: PARTNER 3 - 2 Years data just published in JACC. The primary endpoint remained significantly lower with TAVR versus SAVR but…

Mar 2, 2021 · 53 shares · 3,184 followers View post →

Luigi

@lpbadano · X

RT @hahn_rt: Just Published: PARTNER 3, 2Yr https://t.co/FZKs3uVxtH Primary endpoint remained significantly lower w/ TAVR vs SAVR, but init…

Mar 2, 2021 · 72 shares · 9,490 followers View post →

Cardiac Interventions

@cardiac_of · X

RT @hahn_rt: Just Published: PARTNER 3, 2Yr https://t.co/FZKs3uVxtH Primary endpoint remained significantly lower w/ TAVR vs SAVR, but init…

Mar 2, 2021 · 72 shares · 1,073 followers View post →

Najdat Bazarbashi نجدت بازارباشي

@NajdatB1 · X

RT @PPibarot: PARTNER 3 - 2 Years data just published in JACC. The primary endpoint remained significantly lower with TAVR versus SAVR but…

Mar 2, 2021 · 53 shares · 741 followers View post →

Rayji Tsutsui, MD, MPH

@rstsutsui · X

RT @hahn_rt: Just Published: PARTNER 3, 2Yr https://t.co/FZKs3uVxtH Primary endpoint remained significantly lower w/ TAVR vs SAVR, but init…

Mar 2, 2021 · 72 shares · 698 followers View post →

Julio Farjat Pasos

@Julio_Farjat · X

RT @PPibarot: PARTNER 3 - 2 Years data just published in JACC. The primary endpoint remained significantly lower with TAVR versus SAVR but…

Mar 2, 2021 · 53 shares · 4,302 followers View post →

Thomas Pilgrim

@ThomPilgrim · X

RT @PPibarot: PARTNER 3 - 2 Years data just published in JACC. The primary endpoint remained significantly lower with TAVR versus SAVR but…

Mar 2, 2021 · 53 shares · 1,037 followers View post →

Thibaut Pommier

@ThibautPommier · X

RT @PPibarot: PARTNER 3 - 2 Years data just published in JACC. The primary endpoint remained significantly lower with TAVR versus SAVR but…

Mar 2, 2021 · 53 shares · 167 followers View post →

Cosyns Bernard

@Cosyns · X

RT @PPibarot: PARTNER 3 - 2 Years data just published in JACC. The primary endpoint remained significantly lower with TAVR versus SAVR but…

Mar 2, 2021 · 53 shares · 2,442 followers View post →

Denisse Tinajero

@dnts_92 · X

RT @hahn_rt: Just Published: PARTNER 3, 2Yr https://t.co/FZKs3uVxtH Primary endpoint remained significantly lower w/ TAVR vs SAVR, but init…

Mar 2, 2021 · 72 shares · 227 followers View post →

Dawn Freeman Pittman

@dfpittman · X

RT @PPibarot: PARTNER 3 - 2 Years data just published in JACC. The primary endpoint remained significantly lower with TAVR versus SAVR but…

Mar 2, 2021 · 53 shares · 302 followers View post →

Enrique Garcia-Sayan, MD, FACC, FASE

@EGarciaSayan · X

RT @PPibarot: PARTNER 3 - 2 Years data just published in JACC. The primary endpoint remained significantly lower with TAVR versus SAVR but…

Mar 2, 2021 · 53 shares · 3,981 followers View post →

Abdelrahman Abushouk, MD, FESC

@AbushoukMD · X

RT @hahn_rt: Just Published: PARTNER 3, 2Yr https://t.co/FZKs3uVxtH Primary endpoint remained significantly lower w/ TAVR vs SAVR, but init…

Mar 1, 2021 · 72 shares · 5,501 followers View post →

Dr. Michael Alexander

@MichaelAlexandp · X

Outcomes 2 Years After Transcatheter Aortic Valve Replacement in Patients at Low Surgical Risk: https://t.co/djTslhXqFf

Mar 1, 2021 · 1 like · 840 followers View post →

Juan Carlos Elizalde:.

@JuanElizalde777 · X

RT @PPibarot: PARTNER 3 - 2 Years data just published in JACC. The primary endpoint remained significantly lower with TAVR versus SAVR but…

Mar 1, 2021 · 53 shares · 2,358 followers View post →

Wail AlkashkariFSCAI,FPICSوائل القشقرى

@AlkashkariWail · X

RT @hahn_rt: Just Published: PARTNER 3, 2Yr https://t.co/FZKs3uVxtH Primary endpoint remained significantly lower w/ TAVR vs SAVR, but init…

Mar 1, 2021 · 72 shares · 17,041 followers View post →

Cróchán O'Sullivan

@coscardio · X

Outcomes 2 Years After Transcatheter Aortic Valve Replacement in Patients at Low Surgical Risk: https://t.co/x8Jat9Z5KY

Mar 1, 2021 · 2 likes · 1,746 followers View post →

Outcomes 2 Years After Transcatheter Aortic Valve Replacement in Patients at Low Surgical Risk.

Mentions per month

Where it's discussed

What people are saying

Abstract in brief

Top posts

All mentions

Aortic Valve Replacement: Insights from the AVATAR Trial Results

TAVI, SAVR, PCI and low risk patients

Sudden Cardiac Death in Sports and Coffee's Health Effects

Mar 19, 2021 This Week in Cardiology Podcast